Clinical Trial Update: Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating BO-112 in combination with pembrolizumab for colorectal and gastric/GEJ cancers with liver metastasis has been terminated, and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• BO-112 (BO-112)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Highlight Therapeutics | Conditions: Colorectal Cancer, Gastric Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-11-29